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The use of synthetic lipophilic molecules derived from 5-aminolevulinic acid (ALA) is currently under investigation to enhance
cellular ALA penetration. In this work we studied the effect of systemic administration to mice of the hexyl ester of ALA (He-
ALA) on porphyrin tissue synthesis as compared to ALA. In most normal tissues as well as in tumour, He-ALA induced less
porphyrin synthesis than ALA after its systemic administration either intravenous or intraperitoneal, although explant organ
cultures exposed to either ALA or He-ALA revealed equally active esterases. The only tissue that accumulated higher
porphyrin levels from He-ALA (seven times more than ALA) was the brain, and this correlated well with a rapid increase in
ALA/He-ALA content in brain after administration of He-ALA. This may be ascribed to a differential permeability to lipophilic
substances controlled by the blood–brain barrier, a feature which could be further exploited to treat brain tumours.
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In recent years, 5-aminolevulinic acid-mediated photodynamic
therapy (ALA-PDT) has become one of the most promising ﬁelds
in photodynamic therapy research. ALA is the pro-drug of the
photosensitiser Protoporphyrin IX (PpIX). After ALA administra-
tion, cells generate PpIX through the haem biosynthetic pathway.
The main advantage of PpIX relative to other photosensitisers is
the short half life of its photosensitising effects, which do not last
longer than 48 h (Kennedy et al, 1990; Fukuda et al, 1992). Besides,
ALA-induced porphyrin ﬂuorescence may also assist in the early
detection of some malignancies (Kriegmair et al, 1996).
Different approaches are currently under investigation to
enhance ALA penetration, such as the application of ALA in various
vehicles and the development of new synthetic molecules derived
from ALA. Lipophilic derivatives of ALA were expected to have
better diffusing properties, and after conversion into the parent
ALA by enzymatic hydrolysis, to give a higher PpIX formation rate.
Photodynamic detection and PDT of bladder carcinoma was
improved by the use of ALA esters (Marti et al, 1999; Lange et
al, 1999). However, in spite of the success of ALA esters on
increasing ALA cell membrane permeation (Kloek and Beijersber-
gen van Henegouwen, 1996; Kloek et al, 1998; Gaullier et al,
1997; Berger et al, 2000; Uehlinger et al, 2000; Casas et al,
2001a), the use of these compounds for the treatment of skin
cancer is still a matter of discussion, due to the fact that they
appear to diffuse slowly across the stratum corneum (Casas and
Batlle, 2002).
Regarding the systemic administration of ALA and its esteriﬁed
derivatives, there is some data concerning i.v. and oral administra-
tion of ALA (Loh et al, 1993; Gil et al, 1999), but to the best of our
knowledge there is as yet no published data regarding the systemic
administration of He-ALA. The aim of this study was, therefore, to
study the effect of the systemic administration of He-ALA on
porphyrin tissue synthesis as compared to ALA.
MATERIALS AND METHODS
Animals
Male BALB/c mice, 12-weeks-old, weighing 20–25 g were used.
They were provided with food (Purina 3, Molinos Rı ￿o de la Plata)
and water ad libitum. A suspension of 1.65610
5 cells of the LM2
cell line (Galli et al, 2000) derived from the murine mammary
adenocarcinoma M2 (Instituto Roffo, Buenos Aires) was subcuta-
neously injected into male BALB/c mice. Experiments were
performed approximately at day 20 after implantation. Tumours
of the same uniform size were employed (1 cm diameter). Animals
received human care and were treated in accordance with guide-
lines established by the Animal Care and Use Committee of the
Argentine Association of Specialists in Laboratory Animals
(AADEALC), in full accord with the UK Guidelines for the Welfare
of Animals in Experimental Neoplasia (UKCCCR, 1988).
Drugs
ALA was purchased from SIGMA Chem Co., St. Louis, MO, USA.
ALA hexyl-ester (He-ALA) was synthesised according to the meth-
od previously described by Casas et al (1999). All other chemicals
were of analytical grade.
ALA administration
The hydrochloric acid salts of ALA and He-ALA were dissolved in
saline in a ﬁnal volume of 0.15 ml immediately before intraperito-
neal (i.p.) injection and in 0.05 ml before intravenous (i.v.) injection.
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At the indicated times after ALA or He-ALA administration,
animals were sacriﬁced. Before killing, mice were injected with
heparin (0.15 ml, 1000 UI) and after sacriﬁce, they were
perfused with 200 ml of sterile saline. The tissue samples were
homogenised in a 4:1 solution of ethyl acetate:glacial acetic
acid mixture. The mixtures were centrifuged for 30 min at
3000 g, and the supernatants were treated with an equal volume
of 5% HCl. Extraction with HCl was repeated until there was
no detectable ﬂuorescence in the organic layer. The aqueous
fraction was used for the determination of porphyrins. For
ﬂuorometric determination, a Shimadzu RF-510 spectroﬂuorom-
eter was used, with an emission wavelength of 604 nm and an
excitation wavelength of 406 nm, employing PpIX as a reference
standard.
ALA and He-ALA determination in brain
ALA was determined by a modiﬁcation of the Mauzerall and
Granick (1956) method. Five minutes after ALA or He-ALA
injection, mice were sacriﬁced and the brain was rinsed carefully.
The tissue was then homogenised in 50 mM Tris HCl buffer
pH 7.4 and centrifuged at 3000 g. The supernatant was
condensed with acetylacetone at 1008C and then centrifuged to
precipitate proteins. The ALA or He-ALA content in the result-
ing supernatant was quantiﬁed at 555 nm after addition of the
Ehrlich reagent. The nanomoles of ALA and He-ALA per gram
of tissue were calculated employing a calibration curve of ALA
and He-ALA.
Organ tissue cultures
The explant tissue culture system developed by Polo et al (1988)
has been used. Explants were ﬂoated in Petri dishes in serum-free
minimal essential Eagle’s medium (MEM), supplemented with
2m M L-glutamine and gentamycin (40 mgm l
71) and incubated
at 378C in presence of 0.6 mM ALA or He-ALA for 3 h. After
ALA or He-ALA exposure, explants of 50 mg were homogenised
in a 4:1 solution of ethyl acetate-glacial acetic acid mixture and
porphyrins extracted and quantiﬁed as described above. Optimal
conditions for incubations and explant sizes were as determined
in a previous work (Fukuda et al, 1989).
Statistical analysis
The unpaired t-test was used to establish the signiﬁcance of differ-
ences between groups. Differences were considered statistically
signiﬁcant when P50.05. Three mice per group were employed.
In vitro experiments were performed three times and run in dupli-
cate.
RESULTS
Dose course of porphyrin synthesis after ALA or He-ALA
administration via i.p.
Figure 1 shows porphyrin synthesis in tumour, normal skin and
skin overlaying the tumour (SOT) after the i.p. administration of
increasing doses of ALA or He-ALA. In all three tissues, ALA
yielded higher levels of porphyrin synthesis than He-ALA.
In tumour tissue 7.5 mg of ALA induced a plateau of
5.23+0.62 mg porphyrin g
71 tissue, whereas He-ALA produced
only a slight increase of porphyrins in a dose dependant way,
reaching a maximal accumulation of 1.68+0.18 mgg
71 tissue at
10 mg. He-ALA doses higher than 10 mg are lethal to animals,
while ALA doses higher than 30 mg lead to a diminished porphyr-
in synthesis and, at this dose, the mice autopsy reveled peritoneal
thrombus formation.
In normal skin both ALA and He-ALA induced maximal accu-
mulation of porphyrins at a concentration of 5 mg. A similar
pattern was observed in the skin overlaying the tumour (SOT)
for both compounds reaching plateaux also at 5 mg.
Figure 2 shows liver, kidney and brain porphyrin synthesis after
the i.p. administration of ALA or He-ALA. In liver a plateau was
observed with 5 mg ALA. A dose dependent increase in porphyrin
synthesis was observed with He-ALA, reaching a maximum at
10 mg. In kidney the administration of 7.5 mg ALA induced a
maximum amount of porphyrins, while He-ALA produced a slight
peak at 5 mg.
The brain was the only tissue where porphyrins induced from
He-ALA were higher when compared with ALA. A plateau of
1.47+0.12 mg porphyrins g
71 was found with 5 mg of He-ALA,
surpassing 50 times basal porphyrin values. Meanwhile, ALA
administration reached a plateau of 0.48+0.02 mgg
71, only 15
times ground levels.
Time course of porphyrin synthesis after ALA or He-ALA
administration via i.p.
Figure 3 shows porphyrin accumulation for tumour, normal skin
and SOT as a function of time after 5 mg of ALA or He-ALA
administration via i.p. In these tissues, independently of time,
porphyrin accumulation was higher from ALA. In tumour and
SOT both ALA and He-ALA induced a peak in porphyrin synthesis
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Figure 1 Porphyrin accumulation in tumour, skin and skin overlying the
tumour after i.p. administration of increasing ALA or He-ALA doses. Differ-
ent amounts of ALA or He-ALA were injected i.p. to mice. Three hours
later, tissues were excised and porphyrins extracted as detailed in Materials
and Methods. Each data point represents the average of three determina-
tions. Error bars show standard deviations.
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while the peak from He-ALA was at 5 h.
Figure 4 shows porphyrin synthesis in liver, kidney and brain
after ALA or He-ALA administration via i.p. In liver, ALA induced
a peak at 3 h, and He-ALA, a shoulder between 3 and 8 h and then
a decrease in porphyrin synthesis towards basal levels at 24 h after
administration. In kidney ALA induced a peak at 3 h and He-ALA
a broad peak between 1 and 4 h.
In brain He-ALA produced a maximal porphyrin accumulation
of 2.98+0.27 mgg
71 at 5 h after administration, while ALA
induced a maximum of 0.27+0.03 mgg
71 at 4 h. In both cases
values return to basal levels 24 h after administration.
Heart, lung, gut, spleen, bladder and ear tissues showed, in
general, a porphyrin accumulation from ALA twice higher than
that obtained from He-ALA (data not shown).
Comparison of porphyrin tissue proﬁles between ALA and
He-ALA injected via i.p. and i.v.
The proﬁles of porphyrin accumulation in tumour, skin, SOT,
liver, kidney, brain, heart, lung, gut, spleen, bladder and ear after
administration of different doses of ALA and He-ALA i.p. and
i.v. showed that there were no signiﬁcant differences between i.p.
and i.v. administration for most tissues, independently on the
pro-drug used (data not shown).
Porphyrin synthesis in tissue explants from ALA and
He-ALA as an estimation of esterase activities
To determine if the differences on porphyrin accumulation among
tissues were due either to ALA/He-ALA uptake and distribution
or to differential tissue esterase activities, we performed organ
cultures of the different tissues, exposed to either ALA or He-
ALA (Table 1).
We ran tissue explant cultures of tumour, liver, kidney, SOT,
normal skin, spleen, lung, gut, bladder, brain and heart. We found
that in all these tissues, the amount of porphyrins formed from
He-ALA were similar to those obtained from equimolar ALA
concentrations, and 10–15 times above basal values.
ALA and He-ALA accumulation in brain after i.p.
administration
Equimolar concentrations of ALA and He-ALA (10 and 15 mg
respectively) were injected i.p. to mice. Due to the high toxicity
observed for He-ALA leading to rapid death, we sacriﬁced the
animals 5 min after injection. We observed (Table 2) that 6.7 times
more He-ALA is accumulated in brain as compared with ALA.
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Figure 2 Porphyrin accumulation in liver, kidney and brain after i.p. ad-
ministration of increasing ALA or He-ALA doses. Different amounts of
ALA or He-ALA were injected i.p. to mice. Three hours later, tissues were
excised and porphyrins extracted as detailed in Materials and Methods.
Each data point represents the average of three determinations. Error bars
show standard deviations.
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Figure 3 Porphyrin accumulation in tumour, skin and skin overlying the
tumour different times after i.p. administration of ALA or He-ALA. 5 mg of
of ALA or He-ALA were i.p. injected to mice. At different times, tissues
were excised and porphyrins extracted as detailed in Materials and Meth-
ods. Each data point represents the average of three determinations. Error
bars show standard deviations.
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It has already been demonstrated (van den Akker et al, 2000) that
after topical application of He-ALA, the stratum corneum of the
skin acts as a barrier impairing its penetration through the skin.
It has also been observed that topical use of He-ALA restricts
porphyrin accumulation to the site of application (Casas et al,
2001b; Moan et al, 2001), but the same intensity of PpIX ﬂuores-
cence using lower concentrations of ALA esters compared to ALA
was obtained in the tissue layers of normal rat colon (Endlicher et
al, 2001). On the other hand, employing cell lines of different
origins such as lung, bladder, glia, breast, lymphoma, leukemia,
pancreas and colon among others (Luksiene et al, 2001; Casas
and Batlle, 2002) porphyrin formation from He-ALA was not
impaired, on the contrary it was highly increased by esteriﬁcation
of the ALA molecule.
In this work we have found that porphyrin synthesis from He-
ALA is lower than that from ALA in most tissues, and this does
not depend on the dose and time after administration of either
drug nor on the method of systemic administration (i.v. or i.p.)
utilised.
Employing explant organ culture systems, this study has demon-
strated, that porphyrin synthesis from He-ALA is equal to
porphyrin synthesis from ALA in all tissues. The fact that tissue
esterase was equally active in all tissues analysed, indicates that
the ester cleavage is not the limiting step on porphyrin synthesis
from He-ALA. This also shows that the distribution of either
He-ALA, or porphyrins formed from He-ALA, is the reason why
porphyrin accumulation is lower when compared with ALA.
On all these grounds, we hypothesise that on the passage of He-
ALA from the bloodstream to the tissues, the molecule is retained
by vascular structures. The only tissue that accumulates a higher
amount of porphyrins from He-ALA is the brain. The zwitterionic
structure of aminoacids normally makes the penetration of the
lipophilic blood–brain barrier difﬁcult (Krogsgaard-Larsen et al,
2000), consequently, it is expected that the use of more lipophilic
derivatives of ALA would favour their passage into the brain.
The structure of the blood–brain barrier allows lipophilic mole-
cules such as He-ALA to extravasate and reach the brain, whereas the
rest of the capillars retains the molecule. The role of lipophilicity has
long been recognised as being important in central nervous system
(CNS) penetration by chemicals. Measuring the apparent partition
coefﬁcients of the ALA esters between octanol and water (P), it
has been demonstrated that the most potent compounds acting on
the CNS have a log P value of 2+0.5 (Hansch et al, 1987). On
the other hand, Uehlinger et al (2000) determined that the log P
value for He-ALA was 1.8, whereas log P for ALA was 71.5.
Besides having higher lipophilicity, the blood–brain barrier has
speciﬁc transport systems and carrier proteins (Gloor et al, 2001).
Although He-ALA transport has not yet been studied in neurons or
glial cells, in other cell systems ALA and He-ALA seem to be taken
up by distinct mechanisms (Casas and Batlle, 2002; Bermu ￿dez
Moretti et al, 2002). This may be the reason why delivery of He-
ALA to the brain is different from other tissues.
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Figure 4 Porphyrin accumulation in liver, kidney and brain at different
times after i.p. administration of ALA or He-ALA. 5 mg of of ALA or
He-ALA were i.p. injected to mice. At different times, tissues were excised
and porphyrins extracted as detailed in Materials and Methods. Each data
point represents the average of three determinations. Error bars show
standard deviations.
Table 1 Porphyrin synthesis from tissue explants incubated with ALA or He- ALA
Tissue Tumour Liver Spleen Kidney SOT Normal skin Lung Gut Bladder Brain Heart
Control 0.33+0.02 0.24+0.10 1.69+0.13 0.35+0.05 0.39+0.05 0.07+0.09 0.28+0.04 0.78+0.06 0.11+0.03 0.08+0.03 0.31+0.05
ALA 5.17+0.26 3.91+0.45 8.76+0.55 7.16+0.74 2.78+0.33 1.76+0.22 1.62+0.14 7.51+0.35 2.71+0.31 1.44+0.20 5.68+0.66
He-ALA 5.83+0.38 2.89+0.31 9.21+0.82 5.89+0.42 2.64+0.24 1.99+0.15 2.02+0.19 8.04+0.45 2.60+0.17 1.28+0.26 4.73+0.31
Explants were incubated 3 h with 0.6 mM of ALA or He-ALA, porphyrins were extracted and determined as described in Materials and Methods. Controls correspond to tissues
basal porphyrin levels.
Table 2 ALA and He-ALA levels in brain
nmol ALA or He-ALA g brain
71
Control 17+3
ALA 60+5
He-ALA 404+10
15 mg of He-ALA and 10 mg of ALA were administered i.p. to mice. Five minutes
later, mice were sacriﬁced and ALA and He-ALA were determined as described in
Materials and Methods. Controls correspond to basal ALA levels of non-treated
mice.
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He-ALA injection is almost seven times higher than the amount
found after ALA treatment. This correlates well with the seven-fold
increase in brain porphyrin levels from He-ALA as compared with
ALA. Since we cannot differentiate ALA from He-ALA with our
method of determination, we cannot determine if He-ALA leads
to a rapid and sudden death at high concentrations due to a toxi-
city induced per se or if it is rapidly cleaved by brain esterases to
release ALA and hexanol, both of them very harmful compounds
at high concentrations.
The amount of ALA/He-ALA that we found in brain is equal to
0.5 mM after He-ALA injection and 0.073 mM after ALA injection.
The amount of ALA present in CSF of porphyric patients during
acute attacks ranges widely between 0.027 and 21 mM (Sweeney et
al, 1970; Percy and Shanley, 1979; Gorchein and Webber, 1987).
However, we cannot predict from these and our values whether
or not He-ALA resembles the effects of an acute attack.
In conclusion, we propose that the clinical use of a low dose of
He-ALA administered systemically will probably contribute to the
delimitation and treatment of brain tumors, although much care
should be taken regarding side effects and possible toxicity driven
by resulting ALA, He-ALA or its hydrolysis product hexanol.
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